ClinicalTrials.gg
RecruitingNCT07451977Updated Jun 23, 2026

Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia

An interventional study of Usual Oxygen During 6-Minute Walk Test and Supplemental Oxygen During 6-Minute Walk Test in Chronic Respiratory Failure, Hypoxemia and Chronic Obstructive Pulmonary Disease (COPD), sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 6 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Hypoxia with a site in Italy — 4 open to participants now, 5 under way, none of them phase 3. Hypoxia · Italy.

Planned enrollment
4th of 19
114 · median 48
Started
2026
with 1 other
No phase
13 of 26
1 open now
Registered
25th of 26
by date
Lead sponsor
2 of 26
Istituti Clinici Scientifici Maugeri SpA

Among the 26 studies in Hypoxia with a site in Italy, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 25th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

4 of the 26 studies in Hypoxia with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hypoxia with a site in Italy, or all of them as a file.
02

Study summary

The aim of this multicenter crossover trial is to describe the effect of adding a therapeutic dose of exertional oxygen therapy, in terms of exercise performance, gas exchange, heart rate, symptoms perception and subjective easiness of performance, in a cohort of subjects hospitalized in specialized pulmonary rehabilitation centers with a diagnosis of chronic respiratory failure and/or exertional hypoxemia due to chronic obstructive pulmonary disease or interstitial lung disease.

Researchers will compare the walking performance during 6-minute walk test performed with the liters of oxygen administered as prescribed at rest (for patients with chronic respiratory failure) or in room air (for patients with exertional hypoxemia only), to the performance during a 6-minute walk test performed with the double the flow rate prescribed at rest, or with 2 L/min for patients with exertional hypoxemia only. The two tests will be performed in random order, at least 3 hours apart and no later than 24 hours apart from each other.

The main outcome will be the difference between the distance walked in the two 6-minute walk test in the two conditions. Furthermore, will be also collected and compared: the oxygen saturation and heart rate every minute, the initial and final dyspnea and fatigue, as assessed by Borg scale, and the easiness of performance through a dedicated questionnaire. The estimated sample size will be 114 patients.

This study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure.

Read the detailed description

Although supplemental oxygen enhances acute exercise performance in COPD, its long-term impact on quality of life and mortality remains unproven. Current guidelines suggest treating exertional desaturation (SpO2\<90%), but the lack of standardized titration protocols, particularly using the 6MWT, limits clinical consistency. While many patients with chronic respiratory failure (CRF) receive dual-level oxygen prescriptions (rest vs. exercise), it is unclear if this approach yields significant functional gains. Therefore, In light of these considerations, the present multicenter crossover study aims to describe the effect of adding a therapeutic dose of exertional oxygen therapy in terms of:

  1. exercise performance
  2. gas exchange
  3. heart rate
  4. symptom perception
  5. subjective easiness of performance in a cohort of patients hospitalized in specialized pulmonary rehabilitation centers with a diagnosis of chronic respiratory failure and/or exertional hypoxia due to a chronic respiratory disease at the time of discharge from an inpatient rehabilitation attempt.

As secondary aim, the study will also evaluate any difference in the response among different diseases.

This study will be conducted on subjects with chronic respiratory diseases admitted to the Pulmonary Units of the ICS Maugeri , for rehabilitation will be evaluated for inclusion in the protocol. After approval of the project by the Ethical Committee, those who meet the following criteria at the time of discharge will be enrolled in the study.

We will enroll 3 different groups of patients:

A) Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with EH, with an exertional oxygen prescription and a PaO2 > 60mmHg breathing room air at rest; B) Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Respiratory Failure, with a daytime long-term oxygen therapy (LTOT) prescription and a PaO2 \< 60mmHg breathing room air at rest; C) Diagnosis of Interstitial Lung Disease (ILD) with Chronic Respiratory Failure with a daytime long-term oxygen therapy (LTOT) and a PaO2 \< 60mmHg breathing room air at rest.

All patients have to be in a clinically stable condition for at least one month with optimized therapy during hospitalization.

Exclusion criteria will include: presence of lung diseases other than COPD or ILD; patients requiring a resting oxygen flow rate greater than 6 L/min; patients with orthopedic, cognitive, or neurological conditions that may affect test outcomes; patients with recent cardiovascular or cerebrovascular events within the previous three months; and cognitive impairment evaluated by Mini-Mental State Examination (MMSE) score as \< 25.

With a cross-over multicenter randomized design, at the time of discharge, all patients will perform two 6-Minute Walking Tests in a random order under the following conditions:

  1. O2REST: Liters of oxygen will be administered as prescribed at rest (for patients with CRF), or in room air (for patients with EH only);
  2. O2PLUS: Liters of oxygen therapy will be set at double the flow rate compared to the resting prescription, or at 2 L/min for patients with EH.

The 6MWT will be performed, according to the ATS/ERS guidelines, along a flat corridor of at least 20 meters. Each patient will receive standardized pre-test instructions and verbal encouragement at every minute during the test. The two tests will be performed at least 3 hours apart and no later than 24 hours apart from each other. All patients will perform the tests using nasal prongs and a stroller (liquid oxygen). The stroller will be either held by the patients or transported via a backpack or rollator. When patients perform the test in room air, they will carry the stroller with no oxygen supply.

The following anthropometric and clinical measures will be collected at admission: age, BMI, diagnosis, blood gas analysis (PaO2, PaCO2, pH) at rest breathing room air, time from diagnosis, time from first oxygen prescription, spirometry (FEV1, FVC, IT, RV).

The following data will be recorded during the two 6MWT tests:

  • every minute: distance walked; oxygen saturation, heart rate;
  • initial and final: blood Pressure, Borg Dyspnea Scale (BORGD), Borg Fatigue Scale (BORGF);
  • after three minutes (recovery phase): oxygen saturation, heart rate, Borg Dyspnea Scale (BORGD), Borg Fatigue Scale (BORG).

To evaluate the patient-reported easiness of performance at the end of the second test, a dedicated questionnaire will be administered.

The "oxygen response" will be the primary outcome, defined as the 6-min walk distance using supplemental oxygen (O2PLUS) minus the 6-min walk distance using O2 quantity prescribed at rest (O2REST).

The sample size calculation was done about previous literature study data on 6-minute walk distance, assuming a two-sided α level of 0.01 and a power of 90% and including a 15% dropout rate, according to the diseases: in GROUP A, a sample size of at least 41 patients will be necessary to detect a clinically relevant difference of 28 meters in 6MWD (SD 44); in GROUP B, a sample size of at least 22 patients will be necessary to detect a clinically relevant difference of 37 meters in 6MWD (SD 40); in GROUP C, a sample size of at least 50 patients will be necessary to detect a clinically relevant difference in 6MWD of 13 meters (SD 30) between the two conditions.

The data will be analyzed using STATA 12 (StataCorp, LLC) and GraphPad Prism 8 (GraphPad Software, Boston, MA, US). Baseline characteristics and outcomes will be summarized with descriptive statistics. Continuous variables will be expressed as mean ± standard deviation (SD) or median (interquartile range, IQR) if not normally distributed. Categorical variables will be presented as percentages.

Patients who increased their 6MWD by at least 30 meters due to O2_suppl. were defined as "oxygen responders". A statistical comparison between tests for paired data will be performed using paired t-tests if the variables are normally distributed, or the Wilcoxon signed-rank test if the variables are not normally distributed. The analysis will be conducted within groups, and an additional analysis will be performed by pooling the data into a single group. Furthermore, a linear regression analysis will be carried out to assess whether the changes induced by oxygen administration are associated with baseline clinical or anthropometric factors. Differences in all recorded parameters between the two conditions, both in terms of delta (change) and kinetics, will be also calculated. Statistical significance will be set at p \< 0.05.

We expect to observe an improvement gap in terms of performance or symptoms in a high proportion of patients when tested under hyperoxia. However, the proportion of patients who respond to the hyperoxic stimulus, as well as the characteristics of this phenotype, remain unclear to date.

This study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure. In practice, it will help to characterize the acute effects of oxygen administration during exertion, considering the benefits in terms of physical performance and symptom relief. Furthermore, it will support reflections on the economic and social impact of oxygen prescription, initiating a discussion on the appropriate dosing strategy for exertional oxygen therapy.

Condition or disease:

  • Chronic Respiratory Failure
  • Exertional Hypoxemia
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Interstitial Lung Disease

Intervention/treatment

  • Usual Oxygen During 6-Minute Walk Test
  • Supplemental Oxygen During 6-Minute Walk Test
03

Conditions studied

  • Chronic Respiratory Failure
  • Hypoxemia
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Interstitial Lung Disease

Keywords

  • oxygen supplementation
  • 6-minute walk test
  • chronic respiratory failure
  • exertional hypoxemia
  • pulmonary rehabilitation
  • exercise tolerance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Diagnosis of chronic respiratory disease admitted for pulmonary rehabilitation
  • One of the following conditions at discharge:
  • with exertional hypoxemia
  • Chronic obstructive pulmonary disease with chronic respiratory failure requiring long-term oxygen therapy
  • Interstitial lung disease with chronic respiratory failure requiring long-term oxygen therapy
  • Clinically stable condition for at least one month
  • Optimized medical therapy during hospitalization
  • Ability to perform the 6-minute walk test
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Lung diseases other than or interstitial lung disease
  • Resting oxygen flow requirement greater than 4 liters per minute
  • Orthopedic, neurological, or cognitive conditions that may limit walking performance
  • Recent cardiovascular or cerebrovascular events within the previous 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Active comparator
    6-Minute Walk Test With Usual Oxygen or Room Air (O2REST)

    All participants perform the 6-minute walk test with standard oxygen flow (or room air for participants with exertional hypoxemia only). This arm represents the standard condition for comparison. The test may be administered as first or second test, in a random order, according to the crossover design.

    Other: Usual Oxygen During 6-Minute Walk Test

  • Experimental
    6-Minute Walk Test With Supplemental Oxygen (O2PLUS)

    All participants perform the 6-minute walk test using a higher oxygen flow during exercise to evaluate the effects of supplemental oxygen on walking performance and symptoms. The test may be administered as first or second test, in a random order, according to the crossover design.

    Other: Supplemental Oxygen During 6-Minute Walk Test

Interventions

  • OtherUsual Oxygen During 6-Minute Walk Test

    Participants perform the 6-minute walk test using the oxygen flow prescribed at rest for chronic respiratory failure, or room air for participants with exertional hypoxemia only. Oxygen is delivered through nasal cannula using standard equipment. Walking distance, oxygen saturation, heart rate, and symptoms are recorded during the test.

  • OtherSupplemental Oxygen During 6-Minute Walk Test

    Participants perform the 6-minute walk test using supplemental oxygen during exercise. Oxygen flow is set at double the resting prescription for participants with chronic respiratory failure, or at two liters per minute for participants with exertional hypoxemia. Oxygen is delivered through nasal cannula using standard equipment. Walking distance, oxygen saturation, heart rate, and symptoms are recorded during the test.

06

What researchers measure

Primary outcomes

  1. Change in 6-Minute Walk Distance With Supplemental Oxygen

    This outcome measures the difference in walking distance during the 6-minute walk test when participants use supplemental oxygen (O2PLUS) compared to their usual oxygen setting or room air (O2REST). The change is calculated as the distance walked with supplemental oxygen minus the distance walked with usual oxygen or room air. This outcome reflects the short-term effect of supplemental oxygen on exercise performance.

    Time frame: Within 24 hours (during two 6-minute walk tests performed on the same day)

Secondary outcomes

  1. Oxygen Saturation During the 6-Minute Walk Test

    This outcome measures oxygen saturation levels recorded during the 6-minute walk test when participants walk with supplemental oxygen and when they walk with their usual oxygen setting or room air. Oxygen saturation is recorded every minute during the test to evaluate changes in blood oxygen levels during walking.

    Time frame: During each 6-minute walk test

  2. Heart Rate During the 6-Minute Walk Test

    This outcome measures heart rate recorded during the 6-minute walk test under both oxygen conditions. Heart rate is monitored every minute during walking to assess the cardiovascular response to exercise with and without supplemental oxygen.

    Time frame: During each 6-minute walk test

  3. Dyspnea Before and After the 6-Minute Walk Test

    This outcome measures the level of dyspnea reported by participants using the Borg Dyspnea Scale before the test, immediately after the test, and three minutes after recovery. Results are compared between walking with supplemental oxygen and walking with usual oxygen or room air.

    Time frame: Before the test, immediately after the test, and 3 minutes after recovery

  4. Muscles Fatigue Before and After the 6-Minute Walk Test

    This outcome measures perceived fatigue using the Borg Fatigue Scale before the test, immediately after the test, and three minutes after recovery. Fatigue scores are compared between the two oxygen conditions.

    Time frame: Before the test, immediately after the test, and 3 minutes after recovery

  5. Blood Pressure Before and After the 6-Minute Walk Test

    This outcome measures systolic and diastolic blood pressure assessed before and immediately after the 6-minute walk test under both oxygen conditions to monitor physiological response to exercise.

    Time frame: Before and immediately after each 6-minute walk test

Other outcomes

  1. Participant-Reported Perception of Walking Performance

    This outcome measures participants' subjective perception of their walking performance after completing both 6-minute walk tests. Participants rate perceived differences in shortness of breath, fatigue, and overall ability to walk between the two tests using a structured dedicated questionnaire.

    Time frame: Immediately after completion of the second 6-minute walk test

07

Study locations

4 of 6 sites recruiting
08

References and documents

Publications

  • Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017 Apr;23(2):377-381. doi: 10.1111/jep.12629. Epub 2016 Sep 4. PubMed 27592691 ↗
  • Nishiyama O, Miyajima H, Fukai Y, Yamazaki R, Satoh R, Yamagata T, Sano H, Iwanaga T, Higashimoto Y, Nakajima H, Kume H, Tohda Y. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir Med. 2013 Aug;107(8):1241-6. doi: 10.1016/j.rmed.2013.05.015. Epub 2013 Jun 25. PubMed 23806287 ↗
  • Long-Term Oxygen Treatment Trial Research Group; Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA Jr, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016 Oct 27;375(17):1617-1627. doi: 10.1056/NEJMoa1604344. PubMed 27783918 ↗
  • Sharp C, Adamali H, Millar AB. Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev. 2016 Jul 6;7(7):CD011716. doi: 10.1002/14651858.CD011716.pub2. PubMed 27383922 ↗
  • Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, Carlin B, Drummond MB, Ekstrom M, Garvey C, Graney BA, Jackson B, Kallstrom T, Knight SL, Lindell K, Prieto-Centurion V, Renzoni EA, Ryerson CJ, Schneidman A, Swigris J, Upson D, Holland AE. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Nov 15;202(10):e121-e141. doi: 10.1164/rccm.202009-3608ST. PubMed 33185464 ↗
  • Jarosch I, Gloeckl R, Damm E, Schwedhelm AL, Buhrow D, Jerrentrup A, Spruit MA, Kenn K. Short-term Effects of Supplemental Oxygen on 6-Min Walk Test Outcomes in Patients With COPD: A Randomized, Placebo-Controlled, Single-blind, Crossover Trial. Chest. 2017 Apr;151(4):795-803. doi: 10.1016/j.chest.2016.11.044. Epub 2016 Dec 8. PubMed 27940278 ↗
  • Bradley JM, O'Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD004356. doi: 10.1002/14651858.CD004356.pub3. PubMed 16235359 ↗
  • Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2010 Feb;91(2):221-5. doi: 10.1016/j.apmr.2009.10.017. PubMed 20159125 ↗
  • ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. PubMed 12091180 ↗
  • Eiser N, Willsher D, Dore CJ. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. Respir Med. 2003 Apr;97(4):407-14. doi: 10.1053/rmed.2002.1462. PubMed 12693802 ↗
  • Troosters T, Vilaro J, Rabinovich R, Casas A, Barbera JA, Rodriguez-Roisin R, Roca J. Physiological responses to the 6-min walk test in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002 Sep;20(3):564-9. doi: 10.1183/09031936.02.02092001. PubMed 12358329 ↗
  • Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992 Dec;47(12):1019-24. doi: 10.1136/thx.47.12.1019. PubMed 1494764 ↗
  • Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax. 1999 Mar;54(3):213-22. doi: 10.1136/thx.54.3.213. PubMed 10325896 ↗
  • Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014 Dec;44(6):1428-46. doi: 10.1183/09031936.00150314. Epub 2014 Oct 30. PubMed 25359355 ↗
  • Hardinge M, Annandale J, Bourne S, Cooper B, Evans A, Freeman D, Green A, Hippolyte S, Knowles V, MacNee W, McDonnell L, Pye K, Suntharalingam J, Vora V, Wilkinson T; British Thoracic Society Home Oxygen Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for home oxygen use in adults. Thorax. 2015 Jun;70 Suppl 1:i1-43. doi: 10.1136/thoraxjnl-2015-206865. PubMed 25870317 ↗
  • Jolly EC, Di Boscio V, Aguirre L, Luna CM, Berensztein S, Gene RJ. Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia. Chest. 2001 Aug;120(2):437-43. doi: 10.1378/chest.120.2.437. PubMed 11502641 ↗
  • Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med. 2003 Nov 1;168(9):1034-42. doi: 10.1164/rccm.200212-1525OC. Epub 2003 Jul 17. PubMed 12869359 ↗
  • Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981 Mar 28;1(8222):681-6. PubMed 6110912 ↗
  • Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980 Sep;93(3):391-8. doi: 10.7326/0003-4819-93-3-391. PubMed 6776858 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 21 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 5, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Sep 30, 2028
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07451977
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Apr 2, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jun 23, 2026

Study contacts

Mara Paneroni, PhD, MSc
Contact
mara.paneroni@icsmaugeri.it
+39 030 8253 ext. 167
Mara Paneroni, PhD, MSc
principal investigator · ICS Maugeri IRCCS, Respiratory rehabilitation of the Institute of Lumezzane

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion